A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring ovarian, primary peritoneal cancer, Persistent or Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma
Eligibility Criteria
Inclusion Criteria: subjects must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma. Histologic confirmation of the original primary tumor is required. EGFR expression must be positive as determined by an outside reference lab Subjects must have had a treatment-free interval following platinum of <12 mos All subjects must have measurable disease at baseline Subjects must have at least one recurrent lesion to be used to assess response Recovery from effect of recent surgery, radiotherapy or chemotherapy Exclusion Criteria: Subjects with other invasive malignancies (including peritoneal mesotheliomas) Subjects with unstable cardiac disease or MI within 6 mos Subjects with Acute hepatitis Subjects with active or uncontrolled infection A history of prior cetuximab or other therapy which targets the EGFR pathway or prior history of prior chimerized or murine monoclonal antibody therapy
Sites / Locations
- ImClone Investigational Site
- ImClone Investigational Site
- ImClone Investigational Site
- ImClone Investigational Site
- ImClone Investigational Site
Arms of the Study
Arm 1
Experimental
1
400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles